About this trial

To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.

Eligibility criteria

Qualifiers

Patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between March 2019 and March 2024;

Donor had fasting blood glucose and/or HbA1c records

Eastern Cooperative Oncology Group (ECOG) physical fitness score of 0-2

Survived at least 12 weeks after HSCT

Disqualifiers

Active autoimmune diseases such as SLE, rheumatoid arthritis, etc.

Active cardiovascular disease such as uncontrolled arrhythmias, uncontrolled hypertension, congestive heart failure, any Grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) Functional Class, or a history of myocardial infarction in the 6 months prior to screening;

Other serious medical conditions that may limit the patient's participation in this trial (e.g., progressive infection, uncontrolled diabetes);

HIV infection, or chronic infection with hepatitis B virus (HBsAg-positive) or hepatitis C virus (anti-HCV-positive) that cannot be controlled by medications;

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups

Locations

6
The First Affiliated Hospital of Zhengzhou University ZhengzhouHenan, China
Tongji Hospital of Huazhong University of Science and Technology, Wuhan WuhanHubei, China
Li Quan Hospital ShanghaiShanghai Municipality, China
Ruijin Hospital of Shanghai Jiaotong University ShanghaiShanghai Municipality, China

Sponsors and collaborators

Ruijin Hospital

Lead sponsor